Ranolazine: A novel metabolic modulator for the treatment of chronic stable angina

Formulary

Volumn 38, Issue 8, 2003, Pages 461-476

  McBride, Brian F ^a   White, C Michael ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; FATTY OXIDASE INHIBITOR; GLUCOSE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RANOLAZINE; RENEXA; RISPERIDONE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; OXYGEN SUPPLY; QT INTERVAL; REVIEW; STABLE ANGINA PECTORIS;

EID: 0041737667     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, Tex: American Heart Association; 2002.
2. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1):159-168.
3. Trujillo TC, Nolan PE. Ischemic heart disease: Anginal syndromes. In: Koda-Kimble MA, Lee LY, eds. Applied Therapeutics: The Clinical Use of Drugs. Philadelphia, Pa: Lippincott Williams and Wilkins; 2001:15.1-15.10.
4. Lopaschuck GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation. 1997;95(2):313-315.
5. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitcochondrial respiration in failed human and dog myocardium. J Mol Cell Cardiol. 1998;30(9):1757-1762.
6. Sabbah HN, Sharov VG, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1992;24(11):1333-1347
7. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of the heart muscle. Ann Rev Physiol. 1974;36:413-459.
8. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213(3):263-276.
9. Hutter JF, Piper HM, Spieckerman PG. Effects of fatty acid oxidation on efficiency of energy production in rat heart. Am J Physiol. 1985;249(suppl 4 pt 2):H723-H728.
10. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: The clinician's perspective. Heart Fail Rev. 2002;7(2):187-203.
11. Groenwald AB. Hypovolemic shock. In: Parillo JE, Dellinger RP, eds. Critical Care Medicine: Principles of Diagnosis and Management in the Adult. Philadelphia, Pa: Mosby; 2001:471-475.
12. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for an indirect mechanism. J Mol Cell Cardiol. 1996;28(2):341-350.
13. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580-588.
14. Matsumura H, Hara A, Hashizume H, Maruyama K, Abiko Y. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: Comparison with dichloroacetate. Jpn J Pharmacol. 1998;77(1)31-39.
15. Maruyama K, Hara A, Hashizume H, Ushikubi F, Abiko Y. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol. 2000;52(6):709-715.
16. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93(1):135-142.
17. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28(8):1231-1237.
18. Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol. 1990;99(1):5-6.
19. Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol. 1993;109(3):748-750.
20. Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in doges with chronic heart failure. Circ Res. 2002;91(4):278-280.
21. Lodge JP, Lam FT, Perry SL, Giles GR. Ranolazine - A new drug with beneficial effects on renal preservation. Transplantation. 1990;50(5):755-759.
22. McCormack JG, Baracos VE, Barr R, Lopaschuk GD, Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J Appl Physiol. 1996;81(2):905-910.
23. Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 3rd ed. Philadelphia, Pa: W.B. Saunders; 2000.
24. Allely MC, Alps BJ. The effect of the novel anti-anginal compound RS 43285 on myocardial conduction in the anesthetized dog. Br J Pharamacol. 1988;93(2):375-382.
25. Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol. 1996;118(2):249-254.
26. Zygmunt AC, Thomas GP, Belardinelli L, Blackburn B, Antzelevitch C. Ranolazine produces ion channel effects similar to those observed with chronic amiodarone in canine cardiac ventricular myocytes [abstract]. Pacing Clin Electrophysiol. 2002;4(suppl II):414.
27. Song Y, Wu L, Shryock JC, Antzelevitch C, Belardinelli L. Ranolazine suppresses early after depolarizations and terminates venericular tachycardia in a model of Long QT3 syndrome [abstract]. Pacing Clin Electrophysiol. 2003;26(part II):993.
28. Wu L, Song Y, Shryock JC, Li Y, Antzelevitch C, Belardinelli L. Ranolazine attenuates the prolongation of the monophasic action potential and suppresses ventricular tachycardia caused by sea anemone toxin, ATX-III in guinea pig hearts [abstract]. Pacing Clin Electrophysiol. 2003;26(part II):1023.
29. Gralinski MR, Chi L, Park JL, et al. Protective effects of ranolazine on ventricular fibrillation induced by activation of the ATP-dependent potassium channel in the rabbit heart. J Cardiovasc Pharmacol Ther. 1996;1(2):141-148.
30. Anderson JR, Khou S, Nawarskas JJ. Ranolazine: A potential new treatment for chronic stable angina. Heart Dis. 2001;3(4):263-269.
31. Penman AD, Eadie J, Herron WJ, Reilly MA, Rush WR, Liu Y. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Commun Mass Spectrom. 1995;9(14):1418-1430.
32. Herron WJ, Eadie J, Penman AD. Estimation of ranolazine and eleven phase I metabolites in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry with selected-ion monitoring. J Chromatogr A. 1995;712(1):55-60.
33. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20(1):131-138.
34. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. 1994;8(5):741-747.
35. Bagger JP, Botker HE, Thomassen A, Nielsen TT. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther. 1997;11(3):479-484.
36. Thadani U, Ezekowitcz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation. 1994;90(2):726-734.
37. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol. 1999;84(1):46-50.
38. Wolff AA. MARISA: Monotherapy Assessment of Ranolazine in Stable Angina [abstract]. J Am Coll Cardiol. 2000;35(suppl A):408.
39. Chaitman BR, Skettino S, Parker JO, Frantisky N, Kuch J, Wang W, et al. Efficacy of ranolazine as add-on therapy for chronic angina in elderly patients [abstract]. Circulation. 2002;106(suppl 11):330.
40. White HD, Skettino S, Chaitman BR, Pepine CJ, Parker JO, Frantisku N, et al. Anti-anginal efficacy of ranolazine addtion to beta blocker or calcium antagonist therapy with a history of heart failure [abstract]. Circulation. 2002;106(suppl II):349-350.
41. DeQuattro V, Skettino S, Chaitman BR, et al. Comparative antianginal efficacy and tolerability of ranolazine in diabetic and nondiabetic patients: results of the MARISA trial [abstract]. J Am Coll Cardiol. 2001;37(suppl A):1A-648A.
42. Chaitman BR. Improved exercise capacity using a novel pFOX inhibitor as antianginal therapy: Results of the combination assessment of ranolazine in stable angina (CARISA). Data on file, CV Therapeutics; Palo Alto, Calif: 2003.
43. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis. 2001;43(suppl 5):1-45.
44. Tran H, White CM, Chow MS, Kluger J. An evaluation of the impact of gender and age on QT dispersion in healthy subjects. Ann Noninvasive Electrocardiol. 2001;6(2):129-133.
45. White CM, Chow MSS. Cardiac Arrhythmias. In: Koda-Kimble MA, Young LY, eds. Applied Therapeutics: The Clinical Use of Drugs. Philadelphia, Pa: Lippincott Williams and Wilkins; 2001:18.1-18.36.
46. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (Ziprasidone HCI). New York, NY: Pfizer Inc; July 18, 2000:116.
47. Glassman AH, Bigger JT Jr. Antipsychotic drugs: Prolonged QTc interval, Torsade de Pointes, and sudden death. Am J Psychiatry, 2001;158(11):1774-1782.